VERTEX PHARMACEUTICALS INC / MA (VRTX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for VERTEX PHARMACEUTICALS INC / MA (VRTX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 64/100 — a percentile rank of VERTEX PHARMACEUTICALS INC / MA’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $128.4B |
| P / E | 29.2× |
| P / S | 10.2× |
| EV / EBITDA | 23.8× |
| Gross margin | 86.0% |
| Operating margin | 38.0% |
| Net margin | 35.0% |
| Return on equity | 21.8% |
| ROIC | 28.3% |
| Revenue growth | 10.2% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is VERTEX PHARMACEUTICALS INC / MA overvalued? P/E looks overvalued vs its 5-year range; P/S looks fair vs its 5-year range; EV/EBITDA looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from VERTEX PHARMACEUTICALS INC / MA’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact